MXPA05013278A - Composiciones farmaceuticas que comprenden compuestos activos de vitamina d. - Google Patents

Composiciones farmaceuticas que comprenden compuestos activos de vitamina d.

Info

Publication number
MXPA05013278A
MXPA05013278A MXPA05013278A MXPA05013278A MXPA05013278A MX PA05013278 A MXPA05013278 A MX PA05013278A MX PA05013278 A MXPA05013278 A MX PA05013278A MX PA05013278 A MXPA05013278 A MX PA05013278A MX PA05013278 A MXPA05013278 A MX PA05013278A
Authority
MX
Mexico
Prior art keywords
active vitamin
pharmaceutical compositions
compounds
compositions
compound
Prior art date
Application number
MXPA05013278A
Other languages
English (en)
Inventor
Barbara F Laidlaw
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of MXPA05013278A publication Critical patent/MXPA05013278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmaceuticamente que comprenden un compuesto de vitamina D activo en formulaciones de preconcentrados de emulsion, asi como a emulsiones o a emulsiones con gotas de sub-micras producidas de las mismas. Las composiciones comprenden un componente de fase lipofilica, uno o mas tensioactivos, y un compuesto activo de vitamina D. Las composiciones pueden comprender ademas opcionalmente un componente de fase hidrofilica.
MXPA05013278A 2003-06-11 2004-06-10 Composiciones farmaceuticas que comprenden compuestos activos de vitamina d. MXPA05013278A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47734503P 2003-06-11 2003-06-11
US10/841,954 US20050026877A1 (en) 2002-12-03 2004-05-10 Pharmaceutical compositions comprising active vitamin D compounds
PCT/US2004/018440 WO2004110381A2 (en) 2003-06-11 2004-06-10 Pharmaceutical compositions comprising active vitamin d compounds

Publications (1)

Publication Number Publication Date
MXPA05013278A true MXPA05013278A (es) 2006-03-17

Family

ID=33555457

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013278A MXPA05013278A (es) 2003-06-11 2004-06-10 Composiciones farmaceuticas que comprenden compuestos activos de vitamina d.

Country Status (10)

Country Link
US (1) US20050026877A1 (es)
EP (1) EP1631239A4 (es)
JP (1) JP2007500247A (es)
KR (1) KR20060054198A (es)
AU (1) AU2004247128A1 (es)
BR (1) BRPI0411306A (es)
CA (1) CA2528552A1 (es)
MX (1) MXPA05013278A (es)
NO (1) NO20060179L (es)
WO (1) WO2004110381A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
EP1631146A4 (en) * 2003-06-11 2006-12-06 Novacea Inc TREATMENT OF CANCER USING ACTIVE VITAMIN COMPOUNDS ASSOCIATED WITH RADIOTHERAPEUTIC AGENTS AND TREATMENTS
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
WO2006116204A1 (en) * 2005-04-22 2006-11-02 Novacea, Inc. Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof
DK3095447T3 (da) 2006-02-03 2022-01-31 Opko Renal Llc Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
CA2655499C (en) 2006-06-21 2015-10-27 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP3542792B1 (en) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Controlled release 25-hydroxyvitamin d
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
KR101147600B1 (ko) * 2009-02-09 2012-05-21 한올바이오파마주식회사 콜레칼시페롤 또는 이의 유도체를 함유하는 피부질환 치료용 외용제 조성물
CN105796530A (zh) 2010-03-29 2016-07-27 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
CN108273065B (zh) 2011-03-14 2020-07-31 药品配送方案有限公司 一种眼用组合物
EP2819998B1 (en) * 2012-03-01 2022-04-06 Array BioPharma Inc. Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride
US9668974B2 (en) 2012-05-10 2017-06-06 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
KR20170047265A (ko) 2014-08-07 2017-05-04 옵코 아일랜드 글로벌 홀딩스 리미티드 25-하이드록시비타민 d를 이용한 보조요법
EP3436026A1 (en) 2016-03-28 2019-02-06 OPKO Ireland Global Holdings, Ltd. Methods of vitamin d treatment
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
WO2020049564A1 (en) * 2018-09-06 2020-03-12 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Pharmaceutical compositions of fumaric acid esters and vitamin d derivatives and use thereof
MX2021006750A (es) * 2018-12-06 2021-11-17 Lipicare Life Sciences Ltd Nanoemulsiones de vitamina d y usos de las mismas.
CN115350151B (zh) * 2022-09-29 2023-09-12 湖北欣泽霏药业有限公司 一种高稳定性阿法骨化醇液体口服制剂及其制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670190A (en) * 1973-01-10 1987-06-02 Hesse Robert H 1-α-hydroxy vitamin D compounds and process for preparing same
US3932634A (en) * 1973-06-28 1976-01-13 Pfizer Inc. High potency vitamin water dispersible formulations
DE2526938C2 (de) * 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
JPS5312414A (en) * 1976-07-21 1978-02-03 Chugai Pharmaceut Co Ltd Production of preparation containing stable 1alpha-hydroxyvitamines d
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
US5182274A (en) * 1988-09-26 1993-01-26 Teijin Limited Stabilized aqueous preparation of active form of vitamin d3
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
US5763428A (en) * 1990-09-21 1998-06-09 Bone Care International, Inc. Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
US6538037B2 (en) * 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5298246A (en) * 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
ATE144424T1 (de) * 1991-04-09 1996-11-15 Takeda Chemical Industries Ltd Stabilisiertes vitamin d arzneimittel
US5502224A (en) * 1991-06-04 1996-03-26 Marigen, S.A. Biotenside esters and phosphatides with vitamin-D and vitamin-E compounds
US5486509A (en) * 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
NZ254424A (en) * 1992-06-22 1997-09-22 Lunar Corp Pharmaceutical composition and use of 1 alpha hydroxy-pre-vitamin d
JPH0687750A (ja) * 1992-09-08 1994-03-29 Taiyo Yakuhin Kogyo Kk 医薬組成物
CA2096105A1 (en) * 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
CZ284261B6 (cs) * 1993-09-01 1998-10-14 Teijin Limited 1. alfa.,24-(OH)2-vitamín D3 ve formě emulzního prostředku a farmaceutický prostředek pro léčení psoriázy
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
DE69535127T2 (de) * 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
CA2122431C (en) * 1994-04-28 2006-10-10 Reinhold W. Vieth Topical administration of vitamin d to mammals and compositions therefor
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5597575A (en) * 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
ES2144183T3 (es) * 1995-10-30 2000-06-01 Hoffmann La Roche 1-alfa,26-dihidroxi-d-homo-vitamina d3.
US6730679B1 (en) * 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6034074A (en) * 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) * 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
WO1998037869A1 (fr) * 1997-02-27 1998-09-03 Nippon Shinyaku Co., Ltd. Emulsion grasse s'administrant par voie orale
US6426078B1 (en) * 1997-03-17 2002-07-30 Roche Vitamins Inc. Oil in water microemulsion
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6599513B2 (en) * 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US20030044434A1 (en) * 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
JP5005847B2 (ja) * 1997-07-29 2012-08-22 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 親油性化合物用の自己乳化性処方
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US5919986A (en) * 1997-10-17 1999-07-06 Hoffmann-La Roche Inc. D-homo vitamin D3 derivatives
US6521608B1 (en) * 1998-03-27 2003-02-18 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US6552009B2 (en) * 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6218430B1 (en) * 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP1123921A4 (en) * 1998-10-23 2003-08-20 Teijin Ltd VITAMIN D 3 DERIVATIVES? AND MEDICINES FOR INFLAMMATORY RESPIRATORY DISEASES CONTAINING THEM
FR2785284B1 (fr) * 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6524594B1 (en) * 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
PT1202957E (pt) * 1999-07-16 2005-01-31 Leo Pharma As Aminobenzofenonas como inibidoras de il-1beta e tnf-alpha
US6274169B1 (en) * 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6211169B1 (en) * 1999-09-29 2001-04-03 Aesgen, Inc. Stable calcitriol solution for packaging into vials
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
SK8562002A3 (en) * 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
CA2505373A1 (en) * 2002-11-06 2004-05-27 Novacea, Inc. Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2005110435A1 (en) * 2004-05-10 2005-11-24 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
EP1833485A2 (en) * 2005-01-05 2007-09-19 Novacea, Inc. Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof

Also Published As

Publication number Publication date
BRPI0411306A (pt) 2006-07-11
KR20060054198A (ko) 2006-05-22
EP1631239A2 (en) 2006-03-08
WO2004110381A2 (en) 2004-12-23
AU2004247128A1 (en) 2004-12-23
WO2004110381A3 (en) 2006-05-11
EP1631239A4 (en) 2008-03-05
US20050026877A1 (en) 2005-02-03
JP2007500247A (ja) 2007-01-11
CA2528552A1 (en) 2004-12-23
NO20060179L (no) 2006-03-09

Similar Documents

Publication Publication Date Title
MXPA05013278A (es) Composiciones farmaceuticas que comprenden compuestos activos de vitamina d.
BR0214679A (pt) Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
WO2004026231A3 (en) Formulation for lipophilic agents
WO2004064769A3 (en) Methods for making and using topical delivery agents
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2005020913A3 (en) Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
ZA200410109B (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability.
DK1521573T3 (da) Ikke-polymere, lipofile, farmaceutiske implantatsammensætninger til intrakulær anvendelse
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
DE50114067D1 (de) Galenische formulierung
EP2340710A3 (en) Stable emulsion formulation hindering interaction across the water-oil interface
EP1023904A3 (en) Adjuvants for use in vaccines
DE60104206D1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2005055976A3 (de) Pulver enthaltend niedermolekulares dextran und verfahren zu deren herstellung
WO2006129121A8 (en) Cement compositions comprising environmentally compatible defoaming agents and methods of use
ECSP066481A (es) Formulaciones que contienen cobre
WO2002015959A3 (en) Compounds and compositions for delivering active agents
HK1053795A1 (en) New self emulsifying drug delivery system
EP1608395A4 (en) ANTICROPE WITH LK8 PROTEIN AS AN ACTIVE SUBSTANCE
WO2004091368A3 (en) Sea buckthorn compositions and associated methods
GB0008411D0 (en) Pharmaceutical preparations and their manufacture
CA2376303A1 (en) Stabilized vitamin c formulations
WO2000003724A1 (fr) Preparations pour immunotherapie anticancereuse comprenant un constituant somatique bacterien en tant qu'ingredient actif
AU2003900887A0 (en) Poloxamer emulsion preparations

Legal Events

Date Code Title Description
FA Abandonment or withdrawal